Recent developments in cancer vaccines.
The adoptive transfer of cancer Ag-specific effector T cells in patients can result in tumor rejection, thereby illustrating the immune system potential for cancer therapy. Ideally, one would like to directly induce efficient tumor-specific effector and memory T cells through vaccination. Therapeutic vaccines have two objectives: priming Ag-specific T cells and reprogramming memory T cells (i.e., a transformation from one type of immunity to another, for example, regulatory to cytotoxic). Recent successful phase III clinical trials showing benefit to the patients revived cancer vaccines. Dendritic cells (DCs) are essential in generation of immune responses, and as such represent targets and vectors for vaccination. We have learned that different DC subsets elicit different T cells. Similarly, different activation methods result in DCs able to elicit distinct T cells. We contend that a careful manipulation of activated DCs will allow cancer immunotherapists to produce the next generation of highly efficient cancer vaccines.
Baylor Institute for Immunology Research, Baylor University Medical Center, Dallas, TX 75204, USA.
Karolina
K
Palucka
Hideki
H
Ueno
Jacques
J
Banchereau
D017951:Antigen Presentation / Q000276:immunology; D000951:Antigens, Neoplasm / Q000008:administration & dosage* / Q000276:immunology* / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology* / Q000627:therapeutic use; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends; D006801:Humans; D007156:Immunologic Memory; D016219:Immunotherapy, Adoptive / Q000379:methods / Q000639:trends; D016032:Randomized Controlled Trials as Topic; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines
J Exp Med. 2008 Dec 22;205(13):3119-31
19047440
N Engl J Med. 2010 Aug 19;363(8):711-23
20525992
Cancer Res. 2009 Apr 1;69(7):3077-85
19293190
J Clin Invest. 1999 Jul;104(2):173-80
10411546
J Clin Invest. 2006 May;116(5):1167-73
16670757
Proc Natl Acad Sci U S A. 2006 May 16;103(20):7783-8
16672373
J Exp Med. 2010 Mar 15;207(3):637-50
20156971
Nat Biotechnol. 2010 Aug;28(8):813-5
20697407
J Clin Invest. 2007 Sep;117(9):2517-25
17786242
J Natl Cancer Inst. 2010 Sep 22;102(18):1388-97
20826737
Science. 2002 Oct 25;298(5594):850-4
12242449
Cancer. 2009 Aug 15;115(16):3670-9
19536890
J Clin Invest. 2008 Jun;118(6):2098-110
18497879
Nat Med. 2009 Apr;15(4):401-9
19252500
Clin Cancer Res. 2009 Jul 15;15(14):4612-21
19584156
Immunity. 2008 Sep 19;29(3):372-83
18799145
Immunity. 2010 Oct 29;33(4):516-29
21029962
Nature. 1998 Mar 19;392(6673):245-52
9521319
Annu Rev Immunol. 2003;21:685-711
12615891
Nat Immunol. 2002 Nov;3(11):991-8
12407406
Cancer Cell. 2009 Aug 4;16(2):91-102
19647220
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
12218188
J Exp Med. 2001 Jan 15;193(2):233-8
11208863
Clin Cancer Res. 2007 Sep 1;13(17):5133-43
17785568
Nature. 2001 Apr 26;410(6832):1107-11
11323675
Nat Immunol. 2009 Jan;10(1):116-125
19029902
Nat Rev Immunol. 2009 Mar;9(3):162-74
19197294
N Engl J Med. 1994 Sep 8;331(10):679-80
8052285
Nat Rev Immunol. 2010 Jul;10(7):490-500
20559327
Blood. 1997 Aug 15;90(4):1458-70
9269763
Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5256-61
17875753
Nat Immunol. 2000 Dec;1(6):515-20
11101874
Immunity. 2005 Mar;22(3):371-83
15780993
Science. 1999 Jun 11;284(5421):1835-7
10364556
Cancer Immunol Immunother. 2009 Aug;58(8):1329-36
19156413
N Engl J Med. 2008 Jun 19;358(25):2704-15
18565863
Nat Rev Immunol. 2004 Dec;4(12):941-52
15573129
J Clin Oncol. 2010 Mar 1;28(7):1099-105
20100959
Cancer Immunol Immunother. 2009 Jul;58(7):1137-47
18677477
Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11895-9
20547850
J Immunol. 2007 Feb 15;178(4):1975-9
17277099
J Immunol. 1996 Aug 15;157(4):1406-14
8759720
J Invest Dermatol. 1997 May;108(5):716-20
9129221
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73
12427970
J Exp Med. 2007 May 14;204(5):1037-47
17438063
J Clin Invest. 1996 Jul 1;98(1):70-7
8690806
Science. 1991 Dec 13;254(5038):1643-7
1840703
J Clin Invest. 2007 May;117(5):1204-12
17476350
Immunity. 2008 Sep 19;29(3):497-510
18789730
Cancer Res. 2009 Oct 15;69(20):7895-8
19808962
Curr Opin Immunol. 2008 Oct;20(5):504-11
18573340
J Exp Med. 1997 Aug 29;186(5):673-82
9271583
Annu Rev Immunol. 2001;19:683-765
11244051
Annu Rev Immunol. 2010;28:535-71
20192809
Immunol Today. 1997 Apr;18(4):175-82
9136454
Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1289-94
17229838
Science. 2003 Apr 11;300(5617):339-42
12690202
Cancer J. 2010 Jul-Aug;16(4):318-24
20693842
Nat Med. 2008 Jun;14(6):623-8
18535580
Annu Rev Immunol. 2005;23:651-82
15771583
Nat Rev Immunol. 2002 Feb;2(2):77-84
11910898
J Exp Med. 2009 Aug 3;206(8):1717-25
19581407
Curr Opin Immunol. 1998 Oct;10(5):588-94
9794842
N Engl J Med. 2010 Jul 29;363(5):411-22
20818862
Eur J Immunol. 2009 Apr;39(4):931-8
19197943
Science. 2003 Sep 26;301(5641):1925-8
14512632
Nat Med. 1998 Nov;4(11):1321-4
9809559
Nat Med. 2004 Aug;10(8):801-5
15286781
Nature. 2007 Sep 27;449(7161):419-26
17898760
Exp Biol Med (Maywood). 2008 May;233(5):522-34
18375829
J Exp Med. 2003 Jul 21;198(2):361-7
12874266
Annu Rev Immunol. 2009;27:83-117
19007331
J Exp Med. 2001 Sep 17;194(6):769-79
11560993
Annu Rev Immunol. 2006;24:99-146
16551245
Immunol Rev. 2001 Aug;182:68-79
11722624
Nat Biotechnol. 2002 Feb;20(2):143-8
11821859
Immunity. 2002 Sep;17(3):353-62
12354387
Blood. 2010 Sep 9;116(10):1685-97
20530286
J Exp Med. 2002 Dec 16;196(12):1627-38
12486105
J Clin Oncol. 2003 Nov 1;21(21):4016-26
14581425
Eur J Immunol. 2007 Jun;37(6):1678-90
17492620
Proc Natl Acad Sci U S A. 1996 May 14;93(10):4529-36
8643438
Annu Rev Immunol. 2005;23:23-68
15771565
Cancer Res. 2008 Nov 15;68(22):9441-50
19010919
Curr Dir Autoimmun. 2005;8:124-39
15564719
J Immunol. 2005 Mar 1;174(5):2591-601
15728465
Blood. 2010 Sep 30;116(13):2277-85
20566893